KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Operating Expenses: 2009-2025

Historic Operating Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $136.3 million.

  • Halozyme Therapeutics' Operating Expenses rose 7.45% to $136.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.5 million, marking a year-over-year increase of 7.46%. This contributed to the annual value of $463.8 million for FY2024, which is 5.66% down from last year.
  • Halozyme Therapeutics' Operating Expenses amounted to $136.3 million in Q3 2025, which was up 10.60% from $123.3 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Operating Expenses ranged from a high of $136.3 million in Q3 2025 and a low of $38.3 million during Q1 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Operating Expenses value was $123.3 million (recorded in 2025), while the average stood at $121.7 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Operating Expenses spiked by 212.30% in 2022, and later decreased by 9.85% in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Operating Expenses stood at $45.5 million in 2021, then skyrocketed by 135.30% to $107.0 million in 2022, then increased by 20.58% to $129.0 million in 2023, then declined by 5.04% to $122.5 million in 2024, then increased by 7.45% to $136.3 million in 2025.
  • Its Operating Expenses was $136.3 million in Q3 2025, compared to $123.3 million in Q2 2025 and $123.3 million in Q1 2025.